Since their discovery, iPSCs have been widely used for the modelling of genetic disorders and multiple reports have highlighted the suitability of reprogramming as a platform for drug discovery studies1836. In an analogous manner, different strategies have been used for the modelling of human cancer23101112131415 including the generation of induced pluripotent cancer cells by reprogramming of cancer cells to a pluripotent state4644 and the transformation of differentiated fibroblast by oncogenes and tumour suppressor genes to a cancer stem cell-like phenotype37. More recently, conversion of differentiated cancer cells to a multipotent cancer stem cell phenotype upon overexpression of factors defining GTIC identity has been reported3. Reprogramming of differentiated glioma cells to glioma stem cells opens the unprecedented opportunity for investigating the dynamic dedifferentiation processes leading to the appearance of GTICs (ref. 3). However, the need for primary tumour material (or glioma cell lines) in where transforming mutations are already present could prevent studies on the role that specific mutations might play during gliomagenesis. Directly addressing the lack of model for studying driver mutations, the Tabar laboratory first reported on the use
